Tongee Medical Technology has completed its Series B funding round worth hundreds of millions of CNY, with 深圳拓金创业投资 and 国联国康基金 investing jointly.
Tongee Medical Technology was founded in August 2016 and is quickly growing into a high-tech medical company with a cutting-edge platform for interventional gastroenterology therapy and related medical devices. The company has created a number of novel medical devices for the treatment of obesity, type 2 diabetes, non-alcoholic fatty liver disease, and other metabolic diseases.
The company's Gastric Bypass Stent System has been recognized by the National Medical Products Administration as a Class III medical device, and the products have just completed the most curial part of the clinical trial process and are now in the follow-up phase.
Tongee Medical Technology has multiple technology platforms in place and has ISO13485 certification. Tongee Medical Technology had nearly ten ongoing research projects and had applied for more than 50 patents as of the end of 2021. Many products are in the clinical trial stage and are being tested in more than 20 well-known tertiary hospitals.
Dr. Zhifeng Xue, Tongee's founder, claims that China has the world's largest chronic disease patient population, with overweight and obesity being major causes. Our products have ushered in a new era in the treatment of chronic diseases, and they have a bright future in both domestic and international markets. The funds will be used for research and development in obesity, type 2 diabetes, non-alcoholic fatty liver disease, and the Gastric Bypass Stent System clinical trial.